Latanoprost

DEA Class; Rx

Common Brand Names; Xalatan, Xelpros, Iyuzeh

• Antiglaucoma, Prostaglandin Agonists

Hypersensitivity to latanoprost, benzalkonium chloride, or other components of product

• Increase in brown pigmentation of the iris (15.5%)
• Blurred vision (5-15%)
• Burning and stinging (5-15%)
• Foreign body sensation (5-15%)
• Itching (5-15%)
• Punctate epithelial keratopathy (5-15%)
• Conjunctival hyperemia (5-15%)
• Upper respiratory tract infection/cold/flu (4%)
• Dry eye (1-4%)
• Excessive tearing (1-4%)
• Eye pain (1-4%)
• Lid crusting (1-4%)
• Lid edema (1-4%)
• Lid erythema (1-4%)
• Lid discomfort/pain (1-4%)
• Photophobia (1-4%)
• Chest pain/angina pectoris (1-2%)
• Muscle/joint/back pain (1-2%)
• Rash/allergic skin reactions (1-2%)

Macular edema, including cystoid macular edema, reported; Caution caution with aphakic and pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema

Caution in active intraocular inflammation (eg, iritis/uveitis); generally not for use in patients with active intraocular inflammation; may exacerbate inflammation

Reactivation of herpes simplex keratitis reported; administer with caution in patients with a history of herpetic keratitis; avoid in cases of active herpes simplex keratitis because inflammation may be exacerbated

Take contact lenses out when applying, reinsert at least 15 min later

Bacterial keratitis may result from inadvertent contamination of multidose ophthalmic solutions

Gradual changes in eyelashes and vellus hair (eg, increased length, thickness, pigmentation, number of lashes or hairs, and misdirected growth of eyelashes) may occur; changes are usually reversible upon discontinuation of treatment

May permanently change brown pigmentation of the iris, eyelid skin, and eyelashes; after discontinuation, pigmentation of the iris is likely to be permanent, while pigmentation of periorbital tissue and eyelash changes may be reversible in some patients; inform patients of possibility of increased pigmentation; continue treatment in patients who develop noticeably increased iris pigmentation and examine them regularly

There are no adequate and well-controlled studies in pregnant women

Only use during pregnancy if potential benefits justifies potential risks to the fetus

Not known whether this drug or its metabolites are excreted in human milk; because many drugs are excreted in human milk, exercise caution drug is administered to a nursing woman